Cargando…

Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease

CONTEXT: Thyroid eye disease (TED) is a sight-threatening and debilitating autoimmune condition, with limited therapies available, that often poses diagnostic and therapeutic challenges. In recent years, the treatment landscape has shifted to early intervention with targeted therapy. METHODS: A PubM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kossler, Andrea Lora, Douglas, Raymond, Dosiou, Chrysoula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359446/ https://www.ncbi.nlm.nih.gov/pubmed/36346685 http://dx.doi.org/10.1210/clinem/dgac168

Ejemplares similares

Thyroid Eye Disease: Navigating the New Treatment Landscape
por: Dosiou, Chrysoula, et al.
Publicado: (2021)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

Teprotumumab for the treatment of chronic thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2021)

RF35 | PSAT299 Thyroid Eye Disease Activation After mRNA SARS-CoV-2 Vaccination in Patients With Autoimmune Thyroid Disease
por: Mohamed, Abubakr, et al.
Publicado: (2022)

Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report
por: Lu, Tracy J., et al.
Publicado: (2023)

SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
por: Kaplan, Daniel, et al.
Publicado: (2020)

Improvement of asymmetric thyroid eye disease with teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2022)

Teprotumumab for thyroid eye disease: early response is not required for benefit
por: Ugradar, Shoaib, et al.
Publicado: (2021)

Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2021)

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach
por: Douglas, Raymond S., et al.
Publicado: (2022)

Teprotumumab in advanced reactivated thyroid eye disease
por: Cheng, Olivia T., et al.
Publicado: (2022)

Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

Efficacy and Safety of Teprotumumab in Thyroid Eye Disease
por: Teo, Honeylen Maryl, et al.
Publicado: (2021)

Correction: Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

Early experience with teprotumumab for chronic thyroid eye disease
por: Ozzello, Daniel J., et al.
Publicado: (2020)

Thyroid dermopathy responds to teprotumumab therapy
por: Crespo-Trevino, Ricaurte, et al.
Publicado: (2022)

The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease
por: Simmons, Brittany A., et al.
Publicado: (2022)

Teprotumumab in thyroid eye disease: wonder drug or great divider?
por: Perros, Petros, et al.
Publicado: (2023)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

Effects of teprotumumab on patients with long-standing, active thyroid eye disease
por: Vinson, Kyle B., et al.
Publicado: (2022)

Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study
por: Sears, Connie M., et al.
Publicado: (2021)

A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease
por: Safo, Myra B., et al.
Publicado: (2021)

Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis
por: Douglas, Raymond S.
Publicado: (2018)

The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials
por: Lin, Fei, et al.
Publicado: (2023)

Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab
por: Otero-Marquez, Oscar, et al.
Publicado: (2022)

Audiologic Demonstration of Ototoxicity From Teprotumumab Treatment in a Patient With Thyroid Eye Disease
por: Najjar, Wassim, et al.
Publicado: (2022)

Elasomeran/teprotumumab: Thyroid-eye disease flare, diarrhoea and muscle spasms: case report
Publicado: (2022)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

The Changing Landscape of Hypertension and the Evolving Role of Vasodilatory Beta-Blockers
por: Bakris, George L., et al.
Publicado: (2007)

Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab
por: Bowens, Brendan K., et al.
Publicado: (2022)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study
por: O’Dell, Jordan Miller, et al.
Publicado: (2023)

Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review
por: Bocklud, Brooke E, et al.
Publicado: (2023)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series
por: Chu, Matthew, et al.
Publicado: (2022)

Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases
por: Chiou, Carolina A., et al.
Publicado: (2021)

Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy
por: Adetunji, Modupe O., et al.
Publicado: (2022)

Future Projections in Thyroid Eye Disease
por: Barbesino, Giuseppe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a9646ts6sl6kmq4fabdoeu9ddr